Company Profile

Quanterix Corporation (AKA: Digital Genomics Inc)
Profile last edited on: 5/12/22      CAGE: 4RQD0      UEI: FMFEHF5ACEV2

Business Identifier: Biotech company developing ultrasensitive biomarker detection for healthcare.
Year Founded
2007
First Award
2008
Latest Award
2013
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

113 Hartwell Avenue Suite B14201
Lexington, MA 02421
   (617) 301-9400
   info@quanterix.com
   www.quanterix.com
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

Formerly doing business as Digital Genomics Inc, Quanterix Corporation has developed an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today: effectively digitizing biomarker analysis accurately to measure change for precision health. The firm's Single Molecule Array (Simoa™) technology is at the heart of the platform enabling the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. The firm is digitizing biomarker analysis to accurately measure change for precision health, potentially changing the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. In doing so, Quanterix enables much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. By enabling the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant commercial unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. The firm's unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs, develops and provides ultra-sensitive diagnostic platform for measuring individual proteins. The company's technology enables the detection and quantification of biomarkers in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more; assay kits; and consumables. Its products are used in life science research, oncology, neurology, inflammatory disease, and infectious disease applications

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
250-500
Revenue Range
20M-50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : QTRX
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 2 NIH $2,716,470
Project Title: Single Molecule Fiber Arrays for the Detection of Low Abundance Proteins

Key People / Management

  Kevin E Hrusovsky -- President and CEO

  Martin Madaus -- Chairman and CEO

  Julien Bradley -- Senior Director, Sales & Marketing

  Paul Chapman -- Former President; Chief Executive Officer

  Amol Chaubal -- Chief Financial Officer

  Mary Cortizas -- Vice President of CRO and Laboratory Services

  Scott Douglas -- Sr Director, Technical Development

  David C Duffy -- Chief Technology Officer; Vice President, Research

  David Fournier -- Director Engineering

  William Geist -- Chief Operating Officer

  David Hanlon -- Director Strategic Marketing/Collaborations

  Andreas Jeromin -- Chief Medical Officer

  Nicholas Naclerio -- Chairman

  David Okrongly -- ex CEO

  Ernie Orticerio -- Chief Financial Officer; Vice President, Operations

  Syd Ulvick -- Vice President, Physical and Biological Technologies practice

  David R Walt -- Scientific Founder

  David H Wilson -- Vice President, Product Development